Navigation Links
Oncolytics Biotech Inc. Announces 2008 First Quarter Results
Date:4/30/2008

crease in our investor relations activity, and an increase in compensation costs paid to our board of directors compared to the first quarter of 2007.

During the first quarter of 2008, our office expenses were $324,284 compared to $324,839 for the first quarter of 2007. Our office expense activity has remained consistent in the first quarter of 2008 compared to the first quarter of 2007.

Commitments

As at March 31, 2008, we are committed to payments totaling $2,497,000 during the remainder of 2008 for activities related to clinical trial activity, manufacturing and collaborations. All of these committed payments are considered to be part of our normal course of business.

SUMMARY OF QUARTERLY RESULTS

The following unaudited quarterly information is presented in thousands of dollars except for per share amounts:

-------------------------------------------------------------------------

2008 2007 2006

-------------------------------------------------------------------------

March Dec. Sept. June March Dec. Sept. June

-------------------------------------------------------------------------

Revenue - - - - - - - -

-------------------------------------------------------------------------

Interest

income 180 265 319 359 268 286 320 335

-------------------------------------------------------------------------

Net

loss(3) 3,324 4,085 3,764 3,680 4,113 4,890 3,425 2,988

-------------------------------------------------------------------------

Basic and

diluted

loss per

common

share(3) $0.08 $0.13 $0.09 $0.09 $0.11 $0.13 $0.09 $0.08

-------------------------------------------------------------------------

Total

ass
'/>"/>

SOURCE Oncolytics Biotech Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33

Related biology technology :

1. Oncolytics Biotech Inc. Announces Issuance of 23rd U.S. Patent
2. Oncolytics Biotech Inc. Reports Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
3. Media Advisory - Oncolytics Biotech Inc. to Present at BioPartnering Europe
4. Media Advisory - Oncolytics Biotech Inc. to Present at BIO InvestorForum 2007
5. Oncolytics Biotech Inc. Announces Approval for U.K. Clinical Trial Investigating REOLYSIN(R) in Combination with Cyclophosphamide
6. Oncolytics Biotech Inc. Collaborators to Present Positive Interim Results of U.K. Phase Ia/Ib Combination REOLYSIN(R) and Radiation Clinical Trial
7. Oncolytics Biotech Inc. Announces 2007 Third Quarter Results
8. Media Advisory - Oncolytics Biotech Inc. to Present at Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
9. Media Advisory - Oncolytics Biotech Inc. to Present at Toronto CFA Society
10. Oncolytics Biotech Inc. Announces Issuance of 24th U.S. Patent
11. Oncolytics Biotech Inc. to Present at Annual Vaccine Production Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... CA (PRWEB) , ... July 01, 2015 , ... It ... brain injury (TBI) using single photon emission computed tomography (SPECT) according to ... The study, which examined over 20,000 brain scans and is believed to be the ...
(Date:7/1/2015)... July 1, 2015   Neuraltus Pharmaceuticals, Inc. ... of groundbreaking drugs to treat neurodegenerative diseases such ... Robert G. Miller , M.D., Director of the ... California Pacific Medical Center in San Francisco, has been ... $1.5 million to help fund a Phase 2 ...
(Date:7/1/2015)... ... July 01, 2015 , ... Apex Therapeutics announced today ... Convention in Philadelphia, PA. , The presentation took place on Tuesday, June ... plans for the development of APX3330 for the treatment of pancreatic cancer. A ...
(Date:6/30/2015)... 30, 2015 /PRNewswire/ - Resverlogix Corp. ("Resverlogix") (TSX:RVX) ... of Resverlogix have approved the resolutions relating to: ... of 5,600,000 units at a price of $2.67 ... being comprised of one common share and 0.075358 ... approximately CAD$15 million; and (ii) the amendment to ...
Breaking Biology Technology:Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 2Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 3Brain Scans Can Tell Post-Traumatic Stress Disorder and Traumatic Brain Injury Apart According to New Research by Amen Clinics 4Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 2Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 3Investigator to Receive $1.5 Million Grant from the ALS Association to Help Fund Confirmatory Phase 2 Study of Neuraltus Pharmaceuticals' NP001 4Apex Therapeutics Presented Company Overview at This Year’s BIO International Convention in Philadelphia, PA 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 2Resverlogix Corp. Shareholders Approve Matters Relating to Licensing and Equity Arrangement 3
... Speid & Associates, an international regulatory and drug ... entered into a partnership with Genizon BioSciences to ... Genizon,s proprietary genetic platform. In this challenging ... companies have to watch every dollar that is ...
... bio-manufacturing process to produce methyl ethyl ketone from ... 25 Researchers at Genomatica, Inc., a sustainable ... methyl ethyl ketone (MEK), a commonly used industrial ... than $2 billion. The rapid development breakthrough ...
... Therapeutics,(Nasdaq: NKTR ) today reported its ... December 31, 2008. , ... Howard W. Robin,President and Chief Executive Officer of ... we advanced numerous proprietary drug,candidates into clinical and ...
Cached Biology Technology:Speid & Associates Partners With Genizon BioSciences to Reduce Attrition Rates of New Drug Compounds 2New Genomatica Chemical Process Targets Ailing Ethanol Assets 2New Genomatica Chemical Process Targets Ailing Ethanol Assets 3New Genomatica Chemical Process Targets Ailing Ethanol Assets 4New Genomatica Chemical Process Targets Ailing Ethanol Assets 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 2Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 3Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 4Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 5Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 6Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 7Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 8Nektar Therapeutics Reports Fourth Quarter and Year-End 2008 Financial Results 9
(Date:6/11/2015)... , June 11, 2015 Daon, ... announced today that its IdentityX Mobile Authentication Platform ... IDentity Online) Alliance is an industry consortium launched ... standards for simpler, stronger authentication.  In order to ... pass a rigorous series of tests that measure ...
(Date:6/9/2015)... June 9, 2015   MedNet Solutions , an ... spectrum of clinical research, will be providing demonstrations of ... at the 2015 Drug Information Association (DIA) Annual Meeting ... 15-17.  These presentations will include previews of many exciting ... the upcoming iMedNet 2015 Feature 1 Release. ...
(Date:6/8/2015)... 2015  Trovagene, Inc. (NASDAQ: TROV ), a developer ... its Precision Cancer Monitoring SM platform will be presented ... in San Diego, CA on June ... Integrating Clinical Genomics and Cancer Therapy in ... "We continue to advance our clinical programs and ...
Breaking Biology News(10 mins):Daon's IdentityX Mobile Authentication Platform One of First Products to be Certified by FIDO Alliance 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 2MedNet To Provide Sneak Peeks Of Its iMedNet "2015 Feature 1 Release" At The DIA Annual Meeting 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 2Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 3Clinical Data Featuring Trovagene's Urine-Based Liquid Biopsy Platform to be Presented at Two Upcoming Medical Conferences 4
... Ind. - Discovery that a specific gene is integral to ... deadly toxin in the kernels may lead to ways to ... evaluated the fungal gene ZFR1 and found that it is ... kernels. Production of the toxin decreased when the scientists disabled ...
... Simplifying the process for forming compounds that can be ... plastics, has earned one University of Houston chemist a ... of chemistry in the College of Natural Sciences and ... mathematicians and economists in the United States and Canada ...
... Bioscience Horizons, a unique peer-reviewed journal comprising entirely of ... and Republic of Ireland. Bioscience Horizons ( ... the universities of Leeds, Nottingham, Reading, Chester and Trinity ... forum for the brightest undergraduates in the UK and ...
Cached Biology News:Defining gene's role may lead to prevention of dangerous corn toxin 2Defining gene's role may lead to prevention of dangerous corn toxin 3Simplifying manufacture of drugs, plastics earns UH chemist top honor 2
... The binding specificity and signaling of ... known to be modified by alternative splicing--which ... GPCR SpliceArrays you can perform a classical ... detect the different alternatively spliced forms of ...
... sensitivity of DNA detection has been improved. With ... agarose gel can be detected > 20 ng. ... purified by organic solvent extraction or with other ... well.) DNA excised from agarose gel can ...
Mouse monoclonal antibody raised against a partial recombinant ST3GAL2. NCBI Entrez Gene ID = ST3GAL2...
... Serum-free adapted Sf9 derivative for high-yield ... Sf9 Cells are derived from a high-yielding ... in Novagen serum-free TriEx Insect Cell Medium, ... and protein yields by either baculovirus infection ...
Biology Products: